33 publications
| Name | Date | Type | Actions |
|---|---|---|---|
[AUDIO] Présentation des résultats 2019 Présentation analystes & investisseurs - 26 mars 2020 |
Annual Report | ||
2019 annual results: group sales €396.0M, up 6.1% at constant exchange rates. Net income group share: €28.6M (7.2% of sales) At its meeting on March 24, 2020, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the 2019 financial statements. The auditors have completed their audit of the financial statements and will shortly issue their report thereon. |
Public releases | ||
2019 annual results
|
Annual Report | ||
Covid-19: Vetoquinol donates masks to neighboring healthcare facilities Vetoquinol S.A, the animal health laboratory based in Lure (70) has decided to donate more than 6000 masks to hospitals and associations in the region. This is a civic action to help, amongst others, hospitals in the Belfort Montbéliard, Vesoul and Saint-Rémy regions. |
Public releases | ||
Vetoquinol to acquire rights for Profender® and Drontal® from Elanco Animal Health for the European economic area and the UK February 12 th , 2020 (Lure, France) - Vetoquinol has agreed terms to acquire the European Economic area and UK rights to Profender® and Drontal® product families from Elanco Animal Health. |
Public releases | ||
2019 sales: €396.0 million (Up 7.6%) The Vetoquinol Group posted 2019 sales of €396.0 million, up 7.6% as reported and up 6.1% at constant exchange rates. |
Public releases | ||
Vétoquinol announces opening of its first decentralized R&D center in Canada |
Public releases | ||
2008 calendar of financial communication |
Agenda | ||
Vétoquinol to market and distribute Vetprofen in the United States |
Public releases | ||
3rd quarter revenues confirm promise of For the nine months ended September 30, 2007, Vétoquinol’s total revenues reached €166.0 M, an increase of 11.3% compared with the |
Public releases |